#1 Clinical Trials Search in Europe

Reboxetine

Reboxetine is a medication that has been studied in clinical trials for its potential effectiveness in treating various conditions. This article explores the use of reboxetine in clinical trials for depression, narcolepsy, fibromyalgia, and other disorders. We’ll examine how reboxetine works, its potential benefits, and what researchers have discovered about its efficacy and safety in different patient populations.

Table of Contents

What is Reboxetine?

Reboxetine is a medication primarily used to treat depression. It belongs to a class of drugs called norepinephrine reuptake inhibitors (NRIs). Reboxetine is sometimes referred to by other names in research, including AXS-12, [S,S]-Reboxetine, and PNU-165442G[1][2].

What Conditions Does Reboxetine Treat?

Reboxetine is used to treat several conditions:

  • Major Depressive Disorder (MDD): This is the primary use of reboxetine. It helps alleviate symptoms of depression in adults[3].
  • Narcolepsy: Research is ongoing to evaluate reboxetine’s effectiveness in treating narcolepsy, a sleep disorder that causes excessive daytime sleepiness and sudden attacks of sleep[2].
  • Cataplexy: This is a sudden loss of muscle tone often associated with narcolepsy. Studies are investigating reboxetine’s potential in managing this condition[4].
  • Fibromyalgia: Some research is exploring reboxetine’s potential in treating fibromyalgia, a condition characterized by widespread musculoskeletal pain[1].
  • Attention Deficit Hyperactivity Disorder (ADHD): While not its primary use, some studies have looked at reboxetine’s effects on ADHD symptoms[5].

How Does Reboxetine Work?

Reboxetine works by increasing the levels of a neurotransmitter called norepinephrine in the brain. Neurotransmitters are chemical messengers that help transmit signals between nerve cells. By increasing norepinephrine levels, reboxetine can help improve mood, attention, and energy levels[6].

Dosage and Administration

The dosage of reboxetine can vary depending on the condition being treated and the individual patient. Here are some general guidelines based on the clinical trials:

  • For depression: Doses typically range from 4 mg to 10 mg per day, often divided into two doses[3].
  • For narcolepsy: Studies have used doses up to 10 mg daily[2].
  • For fibromyalgia: Research has explored doses ranging from 4 mg to 10 mg daily[1].

It’s important to note that reboxetine should only be taken as prescribed by a healthcare professional. The dose may be adjusted over time based on your response and any side effects you experience.

Potential Side Effects

Like all medications, reboxetine can cause side effects. Common side effects may include:

  • Dry mouth
  • Constipation
  • Insomnia (difficulty sleeping)
  • Increased sweating
  • Dizziness
  • Nausea

In most cases, these side effects are mild and may improve over time. However, if you experience severe or persistent side effects, you should contact your healthcare provider[5].

Ongoing Research and Future Potential

Researchers are continuing to study reboxetine for various conditions:

  • Narcolepsy and Cataplexy: Several ongoing studies are investigating reboxetine’s potential in treating these sleep disorders. If successful, this could provide a new treatment option for people with narcolepsy[2][4].
  • Fibromyalgia: Research is exploring whether reboxetine can help manage pain and improve quality of life in people with fibromyalgia[1].
  • Post-Traumatic Stress Disorder (PTSD): Some studies are looking at whether reboxetine, in combination with other medications, could help treat symptoms of PTSD[6].
  • Combination Therapy: Researchers are studying the effects of combining reboxetine with other antidepressants to see if this approach could be more effective in treating depression[3].

These ongoing studies may lead to new approved uses for reboxetine in the future, potentially helping more patients with various conditions.

Aspect Details
Main Conditions Studied Major Depressive Disorder, Narcolepsy, Fibromyalgia, PTSD
Mechanism of Action Selective Norepinephrine Reuptake Inhibitor (NRI)
Common Dosages in Trials 4-10 mg per day, often divided into two doses
Administration Method Oral tablets
Primary Outcome Measures Reduction in depressive symptoms, cataplexy attacks, pain scores
Common Side Effects Dry mouth, constipation, insomnia, sweating, dizziness
Notable Findings Potential efficacy in narcolepsy and cataplexy; mixed results in depression
Ongoing Research Focus Narcolepsy, PTSD, attention and emotional processing

FAQ

  • What is reboxetine? Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) that works by increasing the levels of norepinephrine in the brain. It has been studied for its potential effects on mood, attention, and wakefulness in various conditions.
  • What conditions has reboxetine been studied for in clinical trials? Clinical trials have investigated reboxetine for several conditions, including major depressive disorder, narcolepsy, fibromyalgia, posttraumatic stress disorder (PTSD), and attention deficit/hyperactivity disorder (ADHD).
  • How is reboxetine administered in clinical trials? In most clinical trials, reboxetine is administered orally in tablet form. The dosage and frequency can vary depending on the condition being studied and the specific trial protocol. Common dosages range from 4 mg to 10 mg per day, often divided into two daily doses.
  • What are some potential side effects of reboxetine? While side effects can vary, some commonly reported ones in clinical trials include dry mouth, constipation, insomnia, sweating, and dizziness. It's important to note that side effects can differ between individuals and may depend on the dosage and duration of treatment.
  • Are there any ongoing clinical trials for reboxetine? Yes, there are ongoing clinical trials investigating reboxetine for various conditions. For example, studies are currently looking at its potential in treating narcolepsy and cataplexy, as well as its effects on attention and emotional processing in PTSD patients.

Ongoing Clinical Trials on Reboxetine

  • Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Germany Greece Italy Spain

  • Study on How Reboxetine and Methylphenidate Affect Fatigue in Healthy Individuals

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Belgium

Glossary

  • Reboxetine: A selective norepinephrine reuptake inhibitor (NRI) medication that works by increasing the levels of norepinephrine in the brain, potentially affecting mood, attention, and wakefulness.
  • Norepinephrine: A neurotransmitter and hormone that plays a role in attention, focus, and the body's stress response. It is one of the primary targets of reboxetine's action.
  • Major Depressive Disorder (MDD): A mental health condition characterized by persistent feelings of sadness, hopelessness, and loss of interest in activities, often lasting for extended periods and interfering with daily life.
  • Narcolepsy: A chronic sleep disorder characterized by overwhelming daytime drowsiness and sudden attacks of sleep, often accompanied by cataplexy (sudden loss of muscle tone).
  • Fibromyalgia: A chronic condition characterized by widespread musculoskeletal pain, fatigue, sleep, memory, and mood issues.
  • Posttraumatic Stress Disorder (PTSD): A mental health condition triggered by experiencing or witnessing a terrifying event, characterized by flashbacks, nightmares, severe anxiety, and uncontrollable thoughts about the event.
  • Cataplexy: A sudden and transient episode of muscle weakness triggered by strong emotions, typically associated with narcolepsy.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the drug being studied.
  • Double-blind study: A research design in which neither the participants nor the researchers directly involved know who is receiving the experimental treatment and who is receiving a placebo or standard treatment.
  • Efficacy: The ability of a treatment to produce a desired or intended result under ideal circumstances, such as in a controlled clinical trial.

References

  1. https://clinicaltrials.gov/study/NCT00612170
  2. https://clinicaltrials.gov/study/NCT05059223
  3. https://clinicaltrials.gov/study/NCT00636246
  4. https://clinicaltrials.gov/study/NCT03881852
  5. https://clinicaltrials.gov/study/NCT00426946
  6. https://clinicaltrials.gov/study/NCT05133804